Funding Support and Author Disclosures Dr Aggarwal is involved in research funded by the Bristol Myers Squibb-Pfizer alliance and Novartis; and has served as a consultant for Lexicon Pharmaceuticals. Dr Bikdeli is supported by a Career Development Award from the American Heart Association and VIVA Physicians (#938814) (outside of the submitted work); was supported by the Scott Schoen and Nancy Adams IGNITE Award; is supported by the Mary Ann Tynan Research Scientist award from the Mary Horrigan Connors Center for Women’s Health and Gender Biology at Brigham and Women’s Hospital, and the Heart and Vascular Center Junior Faculty Award from Brigham and Women’s Hospital; is a consulting expert, on behalf of the plaintiff, for litigation related to 2 specific brand models of IVC filters (no involvement or financial compensation in 2022 or 2023); is a member of the Medical Advisory Board for North American Thrombosis Forum; and serves in the Data Safety and Monitory Board of the NAIL-IT trial funded by the National Heart, Lung, and Blood Institute, and Translational Sciences. Dr Hussain is funded by a Brigham and Women’s Hospital Heart and Vascular Center Faculty Award and Brigham and Women’s Osteen Award; has received research funds from Vascular Therapies (ACCESS-2 Trial) and Humacyte, Inc (V-012 Trial); and has received consulting fees from Humacyte, Inc. Dr Piazza has received research grants (paid to his institution) from Bristol Myers Squibb/Pfizer, Janssen, Alexion, Bayer, Amgen, BSC, Esperion, and the National Institutes of Health (1R01HL164717-01); and has received consulting fees for advisory roles from BSC, Amgen, PERC, NAMSA, Bristol Myers Squibb, Janssen, Penumbra, and Thrombolex. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.